Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Diagnostic commercialisation company Diaceutics reported annual revenue ahead of market expectations as the launch of its diagnostic DXRX platform bolstered growth.
For the year ended 31 December 2021, revenue grew 10% year-on-year and 2% ahead of market expectations, and adjusted earnings before interest, tax, depreciation, and amortisation, or EBITDA, was up 294% to £2.1 million.
The DXRX platform was launched in October 2020 and in the full year 2021 delivered 57% of total revenues, 'significantly' ahead of the initial target of 20% set in 2020, the company said.
'Diaceutics continues to invest in the development and commercialisation of the DXRX platform, with adjusted EBITDA for the year ended 31 December 2021 in line with market expectations,' it added.
The group's annual audited results will be announced on 22 March 2022.